Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Acalabrutinib Demonstrates Favorable Long-Term Efficacy in CLL

June 18th 2020

Acalabrutinib continued to show favorable efficacy with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.

Axi-Cel Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma

June 18th 2020

Patients with relapsed chronic lymphocytic leukemia and B-cell lymphoma who received the anti-CD19 CAR T-cell therapy FMC63-28Z experienced highly durable rates of remission, according to long-term data from a phase 1/2 study.

Dr. Woyach on the Safety Profiles of BTK Inhibitors in CLL

June 18th 2020

Jennifer Woyach, MD, discusses the safety profiles of BTK inhibitors in patients with chronic lymphocytic leukemia.

Ibrutinib/Venetoclax Triplet Demonstrates Frontline Activity in High-Risk CLL

June 12th 2020

The triplet regimen of ibrutinib, venetoclax, and obinutuzumab demonstrated encouraging response rates with an acceptable safety profile in treatment-naïve patients with high-risk chronic lymphocytic leukemia.

Dr. Al-Sawaf on Updated PFS Data With Venetoclax Plus Obinutuzumab in CLL

June 11th 2020

Othman Al-Sawaf, MD, discusses updated data from the phase 3 CLL14 trial in chronic lymphocytic leukemia.

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 9th 2020

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Lee on the Mechanism of Action of Cirmtuzumab in MCL or CLL

June 9th 2020

Hun Ju Lee, MD, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. Lee on the Mechanism of Action of Cirmtuzumab in MCL or CLL

June 8th 2020

Hun Ju Lee, MD, an associate professor of medicine in the Department of Lymphoma & Myeloma and the Jessica and Jeffrey Brue Endowed Professor of Lymphoma Research at The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. Sharman on the Results of the GENUINE Trial in CLL

June 5th 2020

Jeff P. Sharman, MD, discusses the results of the phase 3 GENUINE trial in chronic lymphocytic leukemia.

Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL

June 3rd 2020

China's National Medical Products Administration has approved zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least 1 prior therapy, as well as for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

Dr. Raphael on the Clinical Implications of the CLL14 Trial

May 8th 2020

Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Dr. Choi on Emerging Treatments in CLL

May 7th 2020

Michael Choi, MD, a medical staff physician and associate clinical professor of medicine at the University of California, San Diego (UCSD) Medical Center, discusses emerging treatments in chronic lymphocytic leukemia (CLL).

Dr. Barr on Novel Combination Strategies in CLL

May 7th 2020

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses novel combination strategies in chronic lymphocytic leukemia (CLL).

Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL

May 6th 2020

Paul M. Barr, MD, discusses the findings from a phase 1/2 trial and the evolution toward triplet therapies in chronic lymphocytic leukemia.

Dr. Pagel on Ongoing Research With BTK Inhibitors in CLL

May 6th 2020

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Umbralisib Plus Ublituximab Improves PFS in Frontline and Relapsed/Refractory CLL

May 5th 2020

A doublet combining umbralisib and ublituximab improved progression-free survival in patients with chronic lymphocytic leukemia.

Dr. Awan on Remaining Questions With BTK Inhibitors and Anti-CD20 Combos in CLL

May 2nd 2020

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

FDA Approves Ibrutinib/Rituximab for Frontline CLL/SLL

April 21st 2020

The FDA has approved an expanded indication of ibrutinib for use in combination with rituximab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Mato Highlights Promise of Investigational Immunotherapeutics in CLL

April 16th 2020

Anthony R. Mato, MD, MSCE, discusses the different research efforts that are being made with immunotherapy in chronic lymphocytic leukemia.

Questions With BTK Inhibitors and Anti-CD20 Combos Require Further Study in CLL

April 10th 2020

Farrukh Awan, MD, discusses the rationale for combining BTK inhibitors with CD20-directed monoclonal antibodies in CLL, sequencing challenges, and remaining questions in the chronic lymphocytic leukemia.